Back to top
more

Vivos Therapeutics (VVOS)

(Delayed Data from NSDQ)

$2.59 USD

2.59
35,745

0.00 (0.00%)

Updated Apr 29, 2024 03:59 PM ET

After-Market: $2.56 -0.03 (-1.16%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Vivos Therapeutics, Inc. (VVOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) delivered earnings and revenue surprises of -17.65% and 3.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 12.50% and 3.97%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -7.50% and 175%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 11.76% and 2.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates

Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Baudax Bio, Inc. (BXRX) Reports Q2 Loss, Misses Revenue Estimates

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of 17.32% and 61.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates

Corcept (CORT) delivered earnings and revenue surprises of -4% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Vivos (VVOS) Stock Options

Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.